Navigation Links
Philippe Généreux, MD, presented with 2012 TCT Young Investigator Award
Date:10/26/2012

MIAMI, FL OCTOBER 26, 2012 Philippe Gnreux, MD was presented the TCT 2012 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award in a ceremony held today during the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The award is given each year to a promising researcher in the field of interventional cardiovascular medicine. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiology.

The award honors the memory of Thomas J. Linnemeier, MD, the former chief of the Indiana Heart Institute, senior vice president of New Ventures, and chief medical officer of Vascular Intervention at Guidant Corp. The purpose of the award, which is accompanied by a $10,000 grant, is to encourage the recipient to maintain a continued commitment and dedication to both patient care and academic research.

An outstanding young academician and a prolific writer, Dr. Philippe Gnreux is a practicing Interventional Cardiologist at Hpital du Sacr-Coeur de Montral. Dr. Gnreux also serves as the Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center where he leads the lab's coronary, peripheral, and structural imaging analyses and services. He received his medical degree from the Universit de Montral, Qubec, Canada, and is currently pursuing a PhD at Erasmus University in Rotterdam, The Netherlands. His research interests include coronary risk stratification/Syntax score, coronary physiology and imaging, percutaneous aortic valve replacement, transradial intervention, drug-eluting stent innovation, and medical simulation.

The winner was selected by Drs. Sheldon Goldberg, Howard C. Herrmann, John W. Hirshfeld Jr. and Robert L. Wilensky from Philadelphia. Gregg W. Stone, MD and Howard C. Hermann, MD jointly presented the award. Dr. Stone is Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Herrmann is Professor of Medicine and the Director of Interventional Cardiology and Cardiac Catheterization Labs at the Hospital of the University of Pennsylvania.

"Dr. Gnreux's tireless commitment to the dual tracks of cardiovascular research and patient care have established him as a rising star in the field, and he is well on his way to becoming a future leader in interventional cardiology," said Drs. Stone and Herrmann.

"We are extremely proud to honor Dr. Philippe Gnreux with the TCT 2012 Young Investigator Award for his exceptional academic achievements and superb clinical skills, as well as his dedication and passion for the field," Martin B. Leon, MD added. Dr. Leon is the Founder of CRF and Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Drs. Leon and Stone both serve as Co-Directors of the Medical Research and Education Division at CRF, and direct the annual TCT scientific sessions.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the XIMA trial presented at TCT 2012
2. Barry D. Rutherford, M.D. presented with Master Clinical Operator Award at TCT 2012
3. Renu Virmani, M.D. presented with 2012 TCT Career Achievement Award
4. Results of the AIDA STEMI MRI sub-study presented at TCT 2012
5. Results of the PC trial presented at TCT 2012
6. Results of the POSEIDON trial presented at TCT 2012
7. 1-year results of ADAPT-DES presented at TCT 2012
8. CRF announces late breaking trials and first report investigations to be presented at TCT 2012
9. New clinical guidelines for managing hypothyroid disease presented in Thyroid Journal
10. Research presented at TCT 2012 will have significant impact on interventional cardiology
11. Typical IBD patients not represented in research studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
Breaking Medicine Technology: